Abstract
For decades, the focus of therapy to mitigate cardiovascular risk has been to lower low density lipoprotein cholesterol (LDL-C), so called “bad cholesterol”. Widespread use of statins has resulted in a large body of clinical experience, which indicates that lower LDL-C levels do indeed correlate with decreased risk of cardiovascular and coronary artery diseases (CVD and CAD). Given these findings, recommended targets for LDL-C levels are continually being revised lower. Interestingly, however, even at low LDL-C levels there remains a substantial residual risk of CVD and CAD, particularly in patients with additional contributing factors. Recent post-hoc analyses of several large lipid modulation trials specifically assessing high density lipoprotein cholesterol (HDL-C) have revealed that increased HDL-C levels confer additional benefit against risk of CVD and CAD, even when LDL-C levels are already low. Human clinical outcomes trials that specifically target increasing HDL-C have not yet been conducted. However, the strong epidemiological inverse correlation between HDL-C and CVD risk remains. Discovery efforts aimed at increasing circulating levels of HDL-C have increased dramatically in recent years. This review will cover recent efforts and agents being developed such as cholesterol ester transfer protein inhibitors and nicotinic acid receptor agonists among other potential strategies.
Keywords: Cardiovascular disease, high density lipoprotein, CETP, LXR, FXR, RXR, GPR109A
Current Medicinal Chemistry
Title: Emerging Strategies and Agents to Lower Cardiovascular Risk by Increasing High Density Lipoprotein Cholesterol Levels
Volume: 16 Issue: 2
Author(s): Scott Greenfeder
Affiliation:
Keywords: Cardiovascular disease, high density lipoprotein, CETP, LXR, FXR, RXR, GPR109A
Abstract: For decades, the focus of therapy to mitigate cardiovascular risk has been to lower low density lipoprotein cholesterol (LDL-C), so called “bad cholesterol”. Widespread use of statins has resulted in a large body of clinical experience, which indicates that lower LDL-C levels do indeed correlate with decreased risk of cardiovascular and coronary artery diseases (CVD and CAD). Given these findings, recommended targets for LDL-C levels are continually being revised lower. Interestingly, however, even at low LDL-C levels there remains a substantial residual risk of CVD and CAD, particularly in patients with additional contributing factors. Recent post-hoc analyses of several large lipid modulation trials specifically assessing high density lipoprotein cholesterol (HDL-C) have revealed that increased HDL-C levels confer additional benefit against risk of CVD and CAD, even when LDL-C levels are already low. Human clinical outcomes trials that specifically target increasing HDL-C have not yet been conducted. However, the strong epidemiological inverse correlation between HDL-C and CVD risk remains. Discovery efforts aimed at increasing circulating levels of HDL-C have increased dramatically in recent years. This review will cover recent efforts and agents being developed such as cholesterol ester transfer protein inhibitors and nicotinic acid receptor agonists among other potential strategies.
Export Options
About this article
Cite this article as:
Greenfeder Scott, Emerging Strategies and Agents to Lower Cardiovascular Risk by Increasing High Density Lipoprotein Cholesterol Levels, Current Medicinal Chemistry 2009; 16 (2) . https://dx.doi.org/10.2174/092986709787002754
DOI https://dx.doi.org/10.2174/092986709787002754 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the Treatment of Chronic Inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Clinical Applicability of Conditioning Techniques in Ischemia-Reperfusion Injury: A Review of the Literature
Current Cardiology Reviews Implications of Dynamic Occupancy, Binding Kinetics, and Channel Gating Kinetics for hERG Blocker Safety Assessment and Mitigation
Current Topics in Medicinal Chemistry Azathioprine in Multiple Sclerosis
Mini-Reviews in Medicinal Chemistry Peptide Based Therapy for Neurological Disorders
Current Protein & Peptide Science Vulnerable Plaque Versus Vulnerable Patient: Emerging Blood Biomarkers for Risk Stratification
Endocrine, Metabolic & Immune Disorders - Drug Targets Patent Selections
Recent Patents on Cardiovascular Drug Discovery Depression and its Relation with Uncontrolled Hypertension and Increased Cardiovascular Risk
Current Hypertension Reviews Catestatin: A Master Regulator of Cardiovascular Functions
Current Medicinal Chemistry Folate Nutrigenetics: A Convergence of Dietary Folate Metabolism, Folic Acid Supplementation, and Folate Antagonist Pharmacogenetics
Drug Metabolism Letters Incremental Value of Two Dimensional Speckle Tracking Echocardiography in the Functional Assessment and Characterization of Subclinical Left Ventricular Dysfunction
Current Cardiology Reviews Cutaneous Complications of Anderson-Fabry Disease
Current Pharmaceutical Design Therapeutic Implications of Immune-endocrine Interactions in the Critically Ill Patients
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Omentin: Linking Metabolic Syndrome and Cardiovascular Disease
Current Vascular Pharmacology The Multiple Electrocardiographic Manifestations of Ventricular Repolarization Memory
Current Cardiology Reviews New Developments in Therapeutic Agents for Legionnaires Disease
Anti-Infective Agents in Medicinal Chemistry ACE Inhibition of Plant Alkaloids Targeted Approach for Selective Inhibition
Mini-Reviews in Organic Chemistry Seeking Novel Targets for Improving In Vivo Macrophage-Specific Reverse Cholesterol Transport: Translating Basic Science into New Therapies for the Prevention and Treatment of Atherosclerosis
Current Vascular Pharmacology Omega-3 Fatty Acids Supplementation in Psychiatric Disorders: A Systematic Review
Current Psychopharmacology Ca2+ Fluxes Involvement in Gene Expression During Cardiac Hypertrophy
Current Vascular Pharmacology Long-Term Bronchodilator Inhaled Therapy in COPD: The Role of Tiotropium Bromidum
Reviews on Recent Clinical Trials